All In Biotech

NDA 203231 · Inforlife

Zoledronic Acid

Zoledronic Acid · Intravenous

Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 2, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

363

118 Phase 3, 24 recruiting

FAERS reports

27,217

25,233 serious, 3,128 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2025.

Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. ( 1.1 ) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of Use : The safety and efficacy of Zoledronic Acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. 1.1 Hypercalcemia of Malignancy Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3 mmol/L] using the formula: cCa in mg/dL = Ca in mg/dL + 0.8 (4 g/dL – patient albumin [1g/dL]). 1.2 Multiple Myeloma and Bone Metastases of Solid Tumors Zoledronic Acid Injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of Zoledronic Acid Injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established.

Mechanism: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although the antiresorptive mechanism is not completely understood, several factors are thought to contribute to this action. In vitro , zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 2, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • ZOLEDRONIC ACID · ZOLEDRONIC ACID EQ 4MG BASE/100ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Zoledronic Acid" as an intervention, any sponsor and status, largest first.

All 363 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • osteonecrosis of jaw2,541
  • fatigue1,931
  • nausea1,778
  • diarrhoea1,776
  • pyrexia1,668
  • off label use1,602
  • pain1,456
  • arthralgia1,433
  • neutropenia1,410
  • vomiting1,409
  • asthenia1,338
  • malignant neoplasm progression1,202

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
200592
2006108
2007227
2008419
2009563
2010324
2011874
2012362
2013385
2014431
2015700
2016931
20171,135
20181,718
20192,096
20202,222
20212,202
20222,342
20232,535
20242,713
20252,908
20261,889

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zoledronic Acid (Zoledronic Ac/Mannitol/0.9nacl)

2024 spending

$86K

Beneficiaries

204

583 claims

Per beneficiary

$422

$1.48 per unit

View as table
YearSpending
2020$43,086
2021$58,148
2022$51,125
2023$73,051
2024$86,081

Part D: Zoledronic Acid (Zoledronic Acid)

2024 spending

$438K

Beneficiaries

1,238

3,990 claims

Per beneficiary

$354

$21.58 per unit

View as table
YearSpending
2020$569,738
2021$549,792
2022$663,024
2023$777,184
2024$438,227

Part D: Zoledronic Acid (Zoledronic Acid/Mannitol-Water)

2024 spending

$1.6M

Beneficiaries

10,061

10,184 claims

Per beneficiary

$156

$1.54 per unit

View as table
YearSpending
2020$1,209,131
2021$1,293,328
2022$1,681,536
2023$1,821,924
2024$1,569,038

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 740 on PubMed

Sponsor: Inforlife

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.